Polymer conjugates of interferon beta-1A and uses
View Patent ↗An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.
1. A composition comprising a glycosylated interferon-beta-1a comprising the amino acid sequence set forth in SEQ ID NO: 41, coupled to a non-naturally-occurring polymer at the N-terminal end of said glycosylated interferon-beta-1a, said polymer comprising a polyalkylene glycol moiety.
2. The composition of claim 1 , wherein the polyalkylene moiety is coupled to said interferon-beta by way of a group selected from an aldehyde group, a maleimide group, a vinylsulfone group, a haloacetate group, plurality of histidine residues, a hydrazine group and an aminothiol group.
3. The composition of claim 1 , wherein the interferon-beta-1a of SEQ ID NO: 41, is an interferon-beta-1a fusion protein.
4. The composition of claim 3 , wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.
5. A physiologically active interferon-beta composition comprising a physiologically active interferon-beta-1a comprising the amino acid sequence of SEQ ID NO: 41, coupled to a polymer comprising a polyalkylene glycol moiety, wherein the interferon-beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is the N-terminal end, wherein the physiologically active interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta-1a in the physiologically active interferon-beta composition has an activity at least 2-fold greater relative to physiologically active interferon-beta-1b, when measured by an antiviral assay.
6. The composition of claim 5 , wherein the interferon-beta-1a is coupled to the polymer by way of a glycan moiety of the interferon-beta-1a.
7. The composition of claim 5 , wherein the interferon-beta-1a is an interferon-beta-1a fusion protein.
8. The composition of claim 7 , wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.
9. A physiologically active interferon-beta composition comprising a physiologically active glycosylated interferon-beta-1a comprising the amino acid sequence of SEQ ID NO: 41, N-terminally coupled to a polymer comprising a polyalkylene glycol moiety, wherein the physiologically active interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta-1a in the physiologically active interferon-beta composition has equal activity relative to physiologically active interferon-beta lacking said moiety, when measured by an antiviral assay.
10. The composition of claim 9 , wherein the interferon-beta is coupled to the polymer by way of a glycan moiety on the interferon-beta.
11. The composition of claim 9 , wherein the interferon-beta-1a is an interferon-beta fusion protein.
12. The composition of claim 11 , wherein the interferon-beta fusion protein comprises a portion of an immunoglobulin molecule.
13. A stable, aqueously soluble, conjugated interferon-beta-1a complex comprising a interferon-beta-1a comprising the amino acid sequence of SEQ ID NO: 41, N-terminally coupled to a polyethylene glycol moiety, wherein the interferon-beta-1a is coupled to the polyethylene glycol moiety by a labile bond, wherein the labile bond is cleavable by biochemical hydrolysis and/or proteolysis.
14. An interferon-beta composition according to claim 1 , wherein the polymer has a molecular weight of from about 5 to 40 kilodaltons.
15. An interferon-beta composition according to claim 9 , wherein the polymer has a molecular weight of from about 5 to 40 kilodaltons.
16. An interferon-beta composition according to claim 13 , wherein the polymer has a molecular weight of from about 5 to 40 kilodaltons.
17. A pharmaceutical composition comprising the interferon-beta composition of claim 14 .
18. A protein comprising the amino acid sequence set forth in SEQ ID NO: 41, coupled to a non-naturally-occurring polymer at the N-terminal end of said protein, said polymer comprising a polyalkylene glycol moiety.
19. A method of preparing the protein of claim 18 , comprising reacting a protein with a non-naturally-occurring polymer under reductive alkylation conditions, said protein comprising the amino acid sequence set forth in SEQ ID NO: 41, and said polymer comprising a polyalkylene glycol moiety and a terminal aldehyde moiety.
20. An interferon-beta composition according to claim 5 , wherein the polymer has a molecular weight of from about 5 to 40 kilodaltons.
21. An interferon-beta composition according to claim 1 , wherein the polymer has a molecular weight of about 20 kilodaltons.
22. An interferon-beta composition according to claim 5 , wherein the polymer has a molecular weight of about 20 kilodaltons.
23. An interferon-beta composition according to claim 9 , wherein the polymer has a molecular weight of about 20 kilodaltons.
24. An interferon-beta composition according to claim 13 , wherein the polymer has a molecular weight of about 20 kilodaltons.
25. An interferon-beta composition according to claim 1 , wherein the polymer has a molecular weight of about 5 kilodaltons.
26. An interferon-beta composition according to claim 5 , wherein the polymer has a molecular weight of about 5 kilodaltons.
27. An interferon-beta composition according to claim 9 , wherein the polymer has a molecular weight of about 5 kilodaltons.
28. An interferon-beta composition according to claim 13 , wherein the polymer has a molecular weight of about 5 kilodaltons.